Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX versus RISEDRONATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX versus RISEDRONATE SODIUM.
FOSAMAX vs RISEDRONATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
None Documented
None Documented
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible.
Category C
Category D/X
Bisphosphonate
Bisphosphonate